Faculty

Institution

Unit

Venue

Maria Cecilia Franco Vega, MD, FACP

Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hospitalist Medicine

Maria Cecilia Franco Vega, Md, Facp is currently serving as a Hospitalist Medicine Associate Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Maria Cecilia Franco Vega, MD, FACP

The University of Texas MD Anderson Cancer Center

Associate Professor

You can click a keyword to filter the displayed items

oncology cancer care medicine lung cancer thoracic oncology radiation oncology immune checkpoint inhibitors immunology cancer treatment immunotherapy respiratory medicine health policy health care patient safety palliative care interstitial lung disease clinical implementation advanced lung disease bronchial neoplasm kidney failure hospital medicine supportive care surgical oncology brain tumor research palliative medicine jama oncology intensive care symptom management end-of-life care care delivery covid-19 pandemic breast oncology thoracic surgery health technology internal medicine health systems medical systems hospital infections quality improvement intracranial pressure case studies spinal oncology neurologic intensive care brain lesion patient management adverse events opioid use disorder cancer pain opioid epidemic opioid overdose acute kidney injury renal care terminal illness cancer management skin cancer prognosis metronomic chemotherapy palliative care providers quality improvement project immune checkpoint inhibition concurrent chemoradiation rapid intracranial response real-world case series untreated brain metastases i-pass handoff tool comprehensive cancer center retrospective analysis long-term clinical distinct patterns auto-reactive antibodies tertiary oncology hospital tertiary care center practice changes surgery health services research translational research emergency medicine family medicine clinical epidemiology emergency nursing public health outcomes research medical sociology health planning nursing management primary care critical care clinic preventive healthcare clinical nursing critical care total quality management health sciences individualized medicine implementation research nursing surgical education international health preventive medicine medical education pain management critical care nurse integrative medicine alternative medicine clinical trials clinical research quality technology quality management nursing science nurse practitioners medical ethics

Notable Scholarly Works

Notable Federal Grants

Collaborators

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity. JCO Precision Oncology (2026)

pharmacologyhigher neurologic toxicitycancer treatmentbronchial neoplasmintracranial efficacyoncologybrain tumor researchreal-world experienceradiation oncologythoracic oncologymetronomic chemotherapylung cancer

A Multi-Institutional Perspective on Tarlatamab Administration and Management of Crs/Icans. Lung Cancer (2025)

managementgovernanceadministrative sciencebusinessstrategic managementtarlatamab administrationinternal controls

From Emails to Emr: Implementing I-Pass Among Inpatient Palliative Care Clinicians at a Comprehensive Cancer Center—a Quality Improvement Initiative. Cancers (2025)

palliative careoutcomes researchterminal illnesssupportive careimplementing i-passoncologyclinical implementationpalliative medicineend-of-life caresymptom managementnursingcancer careimplementation researchfamily medicinepalliative nursinghealth services research

Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From Sclc—a Real-World Case Series: Case Report. Journal of Thoracic Oncology (2025)

Bingnan ZhangKomal B ShahMitchell ParmaKaiwen WangEric K SinghiWhitney LewisMelvin RiveraMehmet AltanJenny PozadzidesXiuning LeNatalie VokesFrank FossellaBarbara O'BrienChenyang WangMartin C TomThomas BeckhamTodd SwansonJulianna BronkSteven H LinMaria Franco VegaJoshua JacomeAlexa HallidayMarcelo NegraoJianjun ZhangDon L GibbonsJohn V HeymachLauren A ByersCarl M Gay

untreated brain metastasesrapid intracranial responsesurgical oncologybrain lesionlung cancerneurologic intensive carecancer researchneuro-oncologymetastasisreal-world case seriesneurologycase studiescritical careoncologybrain tumor researchcancer careintracranial pressurethoracic surgeryspinal oncologythoracic oncologyradiology

Real-World Efficacy and Safety of Tarlatamab in Patients With Relapsed Extensive-Stage Small Cell Lung Cancer.. Journal of Clinical Oncology (2025)

urologycancer treatmentbronchial neoplasmreal-world efficacyoncologyradiation oncologythoracic oncologyimmune checkpoint inhibitorscancer carelung cancer

Risk Factors of Developing Multisystem Immunotherapy-Related Adverse Events Among Patients With Breast Cancer Treated With Immune Checkpoint Inhibitors.. Journal of Clinical Oncology (2025)

cancer immunotherapycancer treatmentbreast cancerbreast oncologyoncologyrisk factorsradiation oncologycellular therapyimmunologyimmunotherapyimmune checkpoint inhibitorscancer care

Using I-Pass to Improve Nursing Handoffs Across the Continuum of Care at a Tertiary Oncology Hospital. BMJ Open Quality (2025)

clinical nursingpatient safetynursingnursing managementcare delivery

1182 Multisystem Immunotherapy-Related Adverse Events Among Patients With Breast Cancer Treated With Immune Checkpoint Inhibitors. Regular and Young Investigator Award Abstracts (2024)

cancer treatmentbreast cancerbreast oncologyoncologyradiation oncologycellular therapyimmunologyimmunotherapyimmune checkpoint inhibitorscancer care

Clo24-066: Cemiplimab Use in Advanced Cutaneous Squamous Cell Carcinoma and Non–Small Cell Lung Cancer: Risk Factors Associated With Mortality. Journal of the National Comprehensive Cancer Network (2024)

cancer managementcemiplimab usecancer treatmentbronchial neoplasmoncologyrisk factorsradiation oncologythoracic oncologydermatologyskin cancercancer carelung cancer

Enhancing Implementation of the I-Pass Handoff Tool Using a Provider Handoff Task Force at a Comprehensive Cancer Center. The Joint Commission Journal on Quality and Patient Safety (2024)

digital healthhealth technologyhealth policyassistive technologyoncologyradiation oncologyi-pass handoff toolcomprehensive cancer center

1
2
3
10 / page

Maria Cecilia Franco Vega, MD, FACP

Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hospitalist Medicine

Maria Cecilia Franco Vega, Md, Facp is currently serving as a Hospitalist Medicine Associate Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Maria Cecilia Franco Vega, MD, FACP

The University of Texas MD Anderson Cancer Center

Associate Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity. JCO Precision Oncology (2026)

A Multi-Institutional Perspective on Tarlatamab Administration and Management of Crs/Icans. Lung Cancer (2025)

managementgovernanceadministrative sciencebusinessstrategic managementtarlatamab administrationinternal controls

From Emails to Emr: Implementing I-Pass Among Inpatient Palliative Care Clinicians at a Comprehensive Cancer Center—a Quality Improvement Initiative. Cancers (2025)

Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From Sclc—a Real-World Case Series: Case Report. Journal of Thoracic Oncology (2025)

Real-World Efficacy and Safety of Tarlatamab in Patients With Relapsed Extensive-Stage Small Cell Lung Cancer.. Journal of Clinical Oncology (2025)

urologycancer treatmentbronchial neoplasmreal-world efficacyoncologyradiation oncologythoracic oncologyimmune checkpoint inhibitorscancer carelung cancer

Risk Factors of Developing Multisystem Immunotherapy-Related Adverse Events Among Patients With Breast Cancer Treated With Immune Checkpoint Inhibitors.. Journal of Clinical Oncology (2025)

cancer immunotherapycancer treatmentbreast cancerbreast oncologyoncologyrisk factorsradiation oncologycellular therapyimmunologyimmunotherapyimmune checkpoint inhibitorscancer care

Using I-Pass to Improve Nursing Handoffs Across the Continuum of Care at a Tertiary Oncology Hospital. BMJ Open Quality (2025)

clinical nursingpatient safetynursingnursing managementcare delivery

1182 Multisystem Immunotherapy-Related Adverse Events Among Patients With Breast Cancer Treated With Immune Checkpoint Inhibitors. Regular and Young Investigator Award Abstracts (2024)

cancer treatmentbreast cancerbreast oncologyoncologyradiation oncologycellular therapyimmunologyimmunotherapyimmune checkpoint inhibitorscancer care

cancer managementcemiplimab usecancer treatmentbronchial neoplasmoncologyrisk factorsradiation oncologythoracic oncologydermatologyskin cancercancer carelung cancer

Enhancing Implementation of the I-Pass Handoff Tool Using a Provider Handoff Task Force at a Comprehensive Cancer Center. The Joint Commission Journal on Quality and Patient Safety (2024)

digital healthhealth technologyhealth policyassistive technologyoncologyradiation oncologyi-pass handoff toolcomprehensive cancer center

1
2
3
10 / page